Anti-NKRP1A/C/D Antibody, clone 16.1

Killer cell lectin-like receptor subfamily B member 1A (UniProt: P27811; also known as NKR-P1A, CD161 antigen-like family member A, CD161a, Lymphocyte antigen 55A (Ly-55A), NKR-P1.7, Natural killer cell surface protein P1-2 (NKR-P1 2)) is encoded by the Klrb1a (also known as Ly55, Ly55a, Nkrp1a) gene (Gene ID: 17057) in mouse. Killer cell lectin-like receptor subfamily B (KLRB) members (NKRP1A/C/D) are a group of receptors primarily expressed on natural killer (NK) cells and some T cells. The expression of KLRB family members and can be influenced by cytokines, developmental cues, and the activation state of the immune cells. These are characterized by a C-type lectin-like domain that allows them to recognize specific carbohydrate structures on target cells. They typically consist of an extracellular region containing one or more C-type lectin-like domains, a single transmembrane domain, and a short cytoplasmic domain that may contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or activation motifs. Some KLRB members have immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that mediate inhibitory signaling. They function as receptors that can transmit either activating or inhibitory signals, influencing NK cell activity and T cell responses. KLRB members play a crucial role in distinguishing between healthy and abnormal (infected or transformed) cells, thereby regulating immune responses. Activation of KLRB members can lead to the cytotoxicity of target cells, while inhibitory signals help prevent autoimmunity and maintain self-tolerance. Studies suggest that NKRP1 molecules expressed on NK cells or transfectants were down-regulated by cross-linking with mAbs or cell surface ligands, and using this phenomenon as a functional assay for NKRP1-ligand interaction revealed that NKRP1F can recognize CLR-x. This antibody also detects other members of the KLRB family (UniProt: P27814 / Q99JB4, also known as NKR-P1C / NKR-P1D). KLRB members have been implicated in various diseases, including cancer, viral infections, and autoimmune disorders. Their role in immune surveillance makes them potential targets for immunotherapy, as enhancing KLRB-mediated cytotoxicity could improve anti-tumor responses. Conversely, dysregulation of KLRB expression or function may contribute to immune evasion by tumors or chronic infections. (Ref.: Aust, J.G., et al. (2009). J Immunol. 183(1):106-16).

YB2/0 rat plasmacytoma cells transfected with NKRP1

Quality Control Testing

Evaluated by Flow Cytometry in C57BL/6 mouse splenocytes.



Flow Cytometry Analysis: 1.0 µg of this antibody detected NKRP1A/C/D in one million C57BL/6 mouse splenocytes.

Tested Applications

Flow Cytometry Analysis: A representative lot detected NKRP1A/C/D in Flow Cytometry applications (Aust, J.G., et al. (2009). J Immunol. 183(1):106-16).

Blocking of Interfering Antibodies: A representative lot blocked NKRP1A/C/D in blocking of Interfering Antibodies applications (Aust, J.G., et al. (2009). J Immunol. 183(1):106-16). A representative lot blocked binding of 10A7 and 2D9 to NKRP1D transfectants.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 16.1 is a rat monoclonal antibody that detects mouse NKRP1A/C/D. It targets an epitope within the extracellular domain.

Purified rat monoclonal antibody IgG2a in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

0.5 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommended storage: +2°C to +8°C.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.